Fibrolamellar Carcinoma New Hope for a Terrible Cancer of Young People
In this video from Rush University Medical Center, Dr. Paul Kent narrates a PowerPoint presentation outlining his team’s experiences in treating patients with FLC.
2021
Fibrolamellar carcinoma: An entity all its own
This publication summarizes the current understanding of fibrolamellar carcinoma based on a review of currently available literature. It outlines the epidemiology, pathology, and biology of FLC, plus provides a high-level overview of the evidence supporting existing therapies for the disease — including surgical, radiotherapy, interventional radiology and systemic treatments. The full article can be read …
Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening
This recent publication describes six new PDX lines derived by direct implantation of tumor specimens, both from the liver (one primary and one recurrent tumor) and metastases. These facilitated the first reported large-scale screening of compounds for the ability to kill dissociated FLC tumor cells in short-term culture (72 hours). Active compounds were also assessed …
A framework for fibrolamellar carcinoma research and clinical trials
This article, published in Nature Reviews Gastroenterology & Hepatology, summarizes the key advances made in understanding the disease since the 2014 discovery that nearly all FLC tumors contain the DNAJB1-PRKACA chimeric fusion transcript. The paper outlines the advances made in understanding the molecular pathways driven by the fusion protein and the potential to identify actionable …
Gemcitabine-Oxaliplatin-Lenvatinib (GEMOX-LEN) For Unresectable Fibrolamellar Carcinoma: Promising Results in First 16 Patients
This poster presentation outlines Rush University Medical Center’s experience in treating FLC patients with a gemcitabine-oxaliplatin-lenvatanib (GEMOX-LEN) combination. This study describes the experiences of 16 patients, most of whom had multiple prior surgeries and systemic therapies, who were judged unresectable. The Rush University team chose gemcitabine-oxaliplatin (GEMOX) based on case reports of GEMOX efficacy in …
Seeking a Cure: The Promise of Immunotherapy
This on-line discussion focuses on understanding the current role of immunotherapy in treating cancer, explores promising new developments in the field and discusses immunotherapy’s potential for treating FLC. In the recorded event, Mark Furth, FCF’s Scientific Director, moderates a conversation with Elizabeth Jaffee, MD, Deputy Director of the Sidney Kimmel Comprehensive Cancer Center at Johns …